191 related articles for article (PubMed ID: 31928796)
1. [Not Available].
Lanthier L; Dussault C; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Feb; 41(2):143-144. PubMed ID: 31928796
[No Abstract] [Full Text] [Related]
2. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Kondo H; Takahashi N
Cardiovasc Res; 2019 May; 115(6):e54-e57. PubMed ID: 31077584
[No Abstract] [Full Text] [Related]
3. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
4. Dapagliflozin Cut Risk of Worsening Heart Failure.
Slomski A
JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
[No Abstract] [Full Text] [Related]
5. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
6. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
7. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
8. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Verma S
Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505
[No Abstract] [Full Text] [Related]
9. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Packer M
Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
[No Abstract] [Full Text] [Related]
10. Dapagliflozin in patients with heart failure and reduced ejection fraction.
Colombo G; Casella R; Cazzaniga A; Casiraghi C;
Intern Emerg Med; 2020 Apr; 15(3):515-517. PubMed ID: 32124206
[No Abstract] [Full Text] [Related]
11. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
12. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
13. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Bhatt DL; Verma S; Braunwald E
Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Packer M
Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Singh JSS; Mordi IR; Vickneson K; Fathi A; Donnan PT; Mohan M; Choy AMJ; Gandy S; George J; Khan F; Pearson ER; Houston JG; Struthers AD; Lang CC
Diabetes Care; 2020 Jun; 43(6):1356-1359. PubMed ID: 32245746
[TBL] [Abstract][Full Text] [Related]
16. NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Adler AI; Douch E; Dunning L; Elliott N
Lancet Diabetes Endocrinol; 2021 May; 9(5):261-263. PubMed ID: 33713596
[No Abstract] [Full Text] [Related]
17. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
18. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Aschenbrenner DS
Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
[TBL] [Abstract][Full Text] [Related]
19. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]